handn18_laptop
handn18_phone

Schedule of Events

Wednesday, February 14, 2018

4:00 p.m. - 6:00 p.m.
Registration

Thursday, February 15, 2018

7:00 a.m. - 5:30 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:50 a.m. - 8:00 a.m.
Day One Welcome
Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston

8:00 a.m. - 9:30 a.m.
General Session I: Oral Cavity
Moderator: Maie St. John, MD, PhD, UCLA Medical Center, Los Angeles

  • How Better Radiation (and Support) Can Impact Quality of Life
    Jolie Ringash, MD, FRCPC, MSc, Princess Margaret Hospital, Toronto 
  • Reconstruction
    P. Daniel Knott, MD, University of California San Francisco, San Francisco 
  • Pre-operative Therapy and Chemoprevention
    William Nassib William Jr., MD, MD Anderson Cancer Center, Houston 

9:30 a.m. - 10:00 a.m.
Coffee Break

10:00 a.m. - 10:45 a.m.
Keynote I: Immunotherapy in Head and Neck Cancer 
Moderator: Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston

  • Julie E. Bauman, MD, MPH, University of Arizona, Tucson, Arizona

10:45 a.m. - 12:15 p.m.
K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session
Moderator: Randall J. Kimple, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 

  • 1: A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T in Patients With PD-L1 Low/Negative Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): CONDOR
    Lillian Siu, MD, Princess Margaret Cancer Centre, Toronto
  • 2: Safety evaluation of nivolumab (Nivo) concomitant with platinum-based chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504
    Maura Gillison, MD, PhD, MD Anderson Cancer Center, Houston
  • 3: Somatic frameshift alterations in tumor suppressor genes may predict anti-PD-1/L1 response in SCCHN
    Glenn Hanna, MD, Dana-Farber Cancer Institute, Boston
  • 4: TCGA Data on HNSCC Suggest Therapy-Specific Implications of Intra-Tumor Heterogeneity
    James Rocco, MD, PhD, The Ohio State University, Columbus, Ohio
  • Discussant
    Young Kim, MD, PhD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
  • 5: OPTIMA—A Phase II Trial of Induction Chemotherapy Response-Stratified RT Dose and Volume De-escalation for HPV+ Oropharynx Cancer: Efficacy, Toxicity, and HPV Subtype Analysis
    Tanguy Seiwert, MD, University of Chicago, Chicago
  • 6: Initial Results from a Phase II Prospective Trial of De-intensified Chemoradiotherapy for Low-Risk HPV-associated Oropharyngeal Squamous Cell Carcinoma
    Bhisham Chera, MD, University of North Carolina, Chapel Hill, North Carolina
  • 7: Toxicity, Swallow Function, and Quality of life (QOL) on MC1273, a Phase II Study of Dose De-escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma (OPSCC)
    Katharine Price, MD, Mayo Clinic, Rochester, Minnesota
  • Discussant
    Sue S. Yom, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco 

12:15 p.m. - 1:15 p.m.
Lunch

Expert Office Hours

  • Beth Beadle, MD, Stanford University, Palo Alto, California
  • Jimmy Caudell, MD, PhD, Moffitt Cancer Center, Tampa, Florida 
  • Kathryn A. Gold, MD, University of California San Diego, La Jolla, California 
  • Patrick Ha, MD, University of California, San Francisco
  • Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana 
  • Maie St. John, MD, PhD, UCLA Medical Center, Los Angeles 
  • Francis P. Worden, MD, University of Michigan Health System Comprehensive Cancer Center, Ann Arbor, Michigan

1:15 p.m. - 2:45 p.m.
General Session II: Tonsil and Base of Tongue
Moderator: Ellie Maghami, MD, FACS, City of Hope, Duarte, California

  • Dose/Volume De-escalation Protocols
    Jimmy Caudell, MD, PhD, Moffitt Cancer Center, Tampa, Florida 
  • Does Chemoselection Have a Role in Oropharynx Cancer?
    Ranee Mehra, MD, Johns Hopkins Hospital, Baltimore 
  • Minimally Invasive Procedures
    Chad Zender, MD, FACS, Case Western Medical Center, Cleveland 

2:45 p.m. - 3:45 p.m.
General Session III: Nasopharynx
Moderator: Beth Beadle, MD, Stanford University, Palo Alto, California

  • Biological Selection for Treatment of Nasopharyngeal Cancer
    Nancy Y. Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York 
  • Timing of Chemotherapy: Induction versus Adjuvant
    Joseph Wee, MD, MBBS, FRCR, FAMS, National Cancer Centre Singapore 
  • Particle Beam Therapy for NPC Re-irradiation
    Jiade Lu, MD, MBA, Shanghai Proton and Heavy Ion Center, Shanghai, China

3:45 p.m. - 4:15 p.m.
Coffee Break

4:15 p.m. - 5:30 p.m.
Tumor Board: Early Stage Disease
Moderator: Danielle N. Margalit, MD, MPH, Dana-Farber Cancer Institute, Boston

  • David Adelstein, MD, Cleveland Clinic, Cleveland 
  • Alexander Lin, MD, University of Pennsylvania, Philadelphia 
  • Ellie Maghami, MD, FACS, City of Hope, Duarte, California 

5:30 p.m. - 6:30 p.m.
Poster Viewing Session and Reception

Friday, February 16, 2018

7:00 a.m. - 6:15 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:55 a.m. - 8:00 a.m.
Day Two Welcome
Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California

8:00 a.m. - 9:30 a.m.
General Session IV: Larynx
Moderator: Anna M. Pou, MD, FACS, LSU Health Sciences Center, New Orleans

  • Preserving the Functional Larynx for Locally Advanced Larynx Cancer
    Wendy Hara, MD, Stanford University, Palo Alto, California
  • Systemic Therapy for Larynx Cancer
    Barbara Ann Burtness, MD, Yale Cancer Center, New Haven, Connecticut
  • Minimally Invasive Approaches in Larynx Cancer
    Mihir R. Patel, MD, Emory University School of Medicine, Atlanta

9:30 a.m. - 10:15 a.m.
Keynote II: New AJCC/UICC Staging System
Moderator: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California

  • Brian O’Sullivan, MD, FASTRO, Princess Margaret Hospital, Toronto, Canada

10:15 a.m. - 10:45 a.m.
Coffee Break

10:45 a.m. - 12:30 p.m.
General Session V: Salivary Glands and Thyroid
Moderator: Patrick Ha, MD, University of California, San Francisco

  • Pathology Review
    Raja Seethala, MD, University of Pittsburgh Medical Center, Pittsburgh
  • Radiation Treatment for Salivary Gland and Thyroid Tumors
    Sue S. Yom, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco 
  • Molecularly Targeted Therapy for Salivary Cancer
    Nicole G. Chau, MD, Dana-Farber Cancer Institute, Boston 
  • Molecular Advances in Thyroid Cancer Management
    Herbert Chen, MD, University of Alabama School of Medicine, Birmingham, Alabama 

12:30 p.m. - 1:30 p.m.
Lunch

Trainee and Early-career Networking Luncheon

  • Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston
  • Randall J. Kimple, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
  • Maie St. John, MD, PhD, UCLA Medical Center, Los Angeles

1:30 p.m. - 3:00 p.m.
Oral Abstract Session
Francis P. Worden, MD, University of Michigan Health System Comprehensive Cancer Center, Ann Arbor, Michigan 

  • 8: A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
    Marcia Brose, MD, PhD, University of Pennsylvania, Philadelphia
  • 9: Multicenter Phase II Trial of Cis/Carboplatin, nAb-Paclitaxel, and CeTUXimab (CACTUX) as First Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Douglas Adkins, MD, Washington University, St. Louis
  • 10: The Negative Impact of Longer Delays to Starting Radiation After Surgery for Head and Neck Cancer Patients in the US
    Jeremy Harris, MD, MPhil, Stanford Radiation Oncology, Stanford, California
  • 11: Panitumumab-IRDye800 as an Optical Agent for Image-guided Surgery in Patients with Squamous Cell Carcinoma
    Rebecca Gao, MS, Stanford University School of Medicine, Stanford, California
  • 12: Multi-institutional Analysis of Next Generation Sequencing of Cell Free Circulating Tumor DNA of Blood Samples from Recurrent and Metastatic Head and Neck Cancer Patients
    Ashleigh Porter, MD, UC San Diego, San Diego
  • 13: HPV structure and integration impact the genomic profile of HPV-positive oropharyngeal squamous cell carcinoma
    Angela Mazul, PhD, University of North Carolina, Chapel Hill, North Carolina
  • 14: Whole-exome sequencing of aggressive cutaneous head and neck squamous cell carcinoma
    Michelle Mierzwa, MD, University of Michigan, Ann Arbor, Michigan
  • 15: Galectin-1 orchestrates immune evasion in head and neck cancer by suppressing T cell recruitment to tumors
    Dhanya Nambiar, PhD, Stanford University, Stanford, California

3:00 p.m. - 4:30 p.m.
Breakout Session I: Early Research and Models
Moderator: Neil Hayes, MD, MPH, UNC School of Medicine, Chapel Hill, North Carolina

  • Radiomics and Mathematical Models
    Heiko Enderling, PhD, Moffitt Cancer Center, Tampa, Florida 
  • Immune Targeting in Head and Neck Squamous Cell Carcinoma: PD-L1, Vaccines and Beyond
    Scott E. Strome, MD, University of Maryland, Baltimore
  • Humanized Laboratory Models to Study the Tumor-stroma Interaction and Translate Immune-directed Therapies
    Antonio Jimeno, MD, PHD, University of Colorado, Aurora, Colorado


Breakout Session II: Survivorship and Acute and Late Effects

Moderator: Barbara Murphy, MD, Vanderbilt University School of Medicine, Nashville, Tennessee

  • Dental Issues for Patients Receiving Radiation
    Evan B. Rosen, DMD, MPH, FACP, Memorial Sloan Kettering Cancer Center, New York 
  • Surveillance and Management of Late Effects of Head and Neck Cancer Therapy
    Katherine A. Hutcheson, PhD, MD Anderson Cancer Center, Houston
  • Management of Mucositis Secondary to Cancer Therapy
    Nikhil G. Rao, MD, Florida Hospital, Orlando, Florida

4:30 p.m. - 5:00 p.m.
Coffee Break

5:00 p.m. - 6:15 p.m.
Tumor Board: Advanced Disease
Moderator: Kathryn A. Gold, MD, University of California San Diego, La Jolla, California

  • June Corry, MD, MBBS, FRACP, FRANZCR, St. Vincent’s Hospital, Fitzroy, Australia
  • Jonathan Irish, MD, MSc, FRCSC, FACS, Princess Margaret Cancer Centre, Toronto
  • Everett Vokes, MD, University of Chicago, Chicago

Saturday, February 17, 2018

7:00 a.m. - 12:00 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:55 a.m. - 8:00 a.m.
Day Three Welcome
Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana

8:00 a.m. - 9:30 a.m.
General Session VI: Immunotherapy Advances in Head and Neck Cancer
Moderator: Robert L. Ferris, MD, PhD, FACS, University of Pittsburgh Cancer Institute, Pittsburgh

  • Immunotherapy in Recurrent Disease
    Michael K. Gibson, MD, PhD, FACP, University Hospitals Cleveland Medical Center, Cleveland 
  • Immunotherapy in Definitive Treatment in Combination with Radiotherapy (RT) and ChemoRT
    Andrew B. Sharabi, MD, PhD, UC San Diego Health, Moores Cancer Center, La Jolla, California
  • Immunotherapy in Neo-adjuvant Treatment
    Ravindra Uppaluri, MD, PhD, Dana-Farber Cancer Institute, Boston

9:30 a.m. - 10:00 a.m.
Coffee Break

10:00 a.m. - 10:45 a.m.
Keynote III: Melanoma of the Head and Neck
Moderator: Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana

  • Carol Rossier Bradford, MD, University of Michigan Health System, Ann Arbor, Michigan

10:45 a.m. - 12:00 p.m.
Tumor Board: Rare Tumors and Non-Melanoma Skin Cancer of the Head and Neck
Moderator: Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana

  • Nishant Agrawal, MD, University of Chicago, Chicago
  • David M. Brizel, MD, FASTRO, Duke Cancer Institute, Durham, North Carolina
  • Ezra Cohen, MD, UC San Diego Health, Moores Cancer Center, La Jolla, California
Copyright © 2017 American Society for Radiation Oncology | Conflict of InterestTerms of Use | Privacy Policy | Contact Us 
251 18th Street South, 8th Floor, Arlington, VA 22202 | Phone: 703-502-1550 | Fax: 703-502-7852